[go: up one dir, main page]

PE20120834A1 - Derivados de furopirimidindiona como moduladores de trpa1 - Google Patents

Derivados de furopirimidindiona como moduladores de trpa1

Info

Publication number
PE20120834A1
PE20120834A1 PE2011001704A PE2011001704A PE20120834A1 PE 20120834 A1 PE20120834 A1 PE 20120834A1 PE 2011001704 A PE2011001704 A PE 2011001704A PE 2011001704 A PE2011001704 A PE 2011001704A PE 20120834 A1 PE20120834 A1 PE 20120834A1
Authority
PE
Peru
Prior art keywords
furopyrimidindiona
derivatives
tetrahydrofide
cra
dioxo
Prior art date
Application number
PE2011001704A
Other languages
English (en)
Inventor
Abraham Thomas
Indranil Mukhopadhyay
Sachin Sundarlal Chaudhari
Nishap Parag Patil
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20120834A1 publication Critical patent/PE20120834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO H, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, ALQUENILO, CICLOALQUILALQUILO, ENTRE OTROS; Z1 Y Z2 SON CADA UNO O, CRa, CON LA CONDICION DE QUE UNO ES O Y EL OTRO CRa; L ES UN LIGADOR DE PREFERENCIA -CH2-; U ES ARILO SUSTITUIDO O NO, TIAZOL, PIRAZOL, IMIDAZOL, OXAZOL, ENTRE OTROS; V ES H, CIANO, NITRO, HALOGENO, HALOALCOXILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(4-TRIFLUOROMETILFENOXI)FENIL]-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROFURO[2,3-d]PIRIMIDIN-5-IL)ACETAMIDA; N-(4,6-DIFLUORO-1,3-BENZOTIAZOL-2-IL)-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROFURO[2,3-d]PIRIMIDIN-5-IL)ACETAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE TRPA 1 UTILES EN EL TRATAMIENTO DE DOLOR, NEURALGIA, MIGRANA, NEUROPATIAS, CIATICA, ENTRE OTROS
PE2011001704A 2009-03-23 2010-03-22 Derivados de furopirimidindiona como moduladores de trpa1 PE20120834A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12

Publications (1)

Publication Number Publication Date
PE20120834A1 true PE20120834A1 (es) 2012-07-25

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001704A PE20120834A1 (es) 2009-03-23 2010-03-22 Derivados de furopirimidindiona como moduladores de trpa1
PE2011001705A PE20120775A1 (es) 2009-03-23 2010-03-23 Derivados de tienopirimidindiona como moduladores de trpa1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001705A PE20120775A1 (es) 2009-03-23 2010-03-23 Derivados de tienopirimidindiona como moduladores de trpa1

Country Status (23)

Country Link
US (4) US20120178766A1 (es)
EP (3) EP2411395B1 (es)
JP (2) JP2012521406A (es)
KR (2) KR20110128898A (es)
CN (3) CN102361874A (es)
AP (1) AP2948A (es)
AU (2) AU2010227225A1 (es)
BR (2) BRPI1013705A2 (es)
CA (2) CA2756535A1 (es)
DK (3) DK2411395T3 (es)
EA (2) EA201190138A1 (es)
ES (3) ES2424341T3 (es)
HK (2) HK1166074A1 (es)
HU (1) HUE024538T2 (es)
IL (2) IL215177A (es)
MX (1) MX2011009822A (es)
PE (2) PE20120834A1 (es)
PL (3) PL2411395T3 (es)
PT (3) PT2411395E (es)
SG (4) SG184767A1 (es)
SI (3) SI2411395T1 (es)
WO (2) WO2010109329A1 (es)
ZA (2) ZA201107650B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013705A2 (pt) 2009-03-23 2016-04-05 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
KR20110132575A (ko) 2009-03-23 2011-12-08 그렌마크 파머수티칼스 에스. 아. Ｔｒｐａ1 조절자로서 융합된 피리미딘디온 유도체
BR112013014692A2 (pt) 2010-12-20 2016-11-29 Glenmark Pharmaceuticals Sa composto e respectivo processo de preparação e composição farmacêutica
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP2014517031A (ja) 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
BR112013031820A2 (pt) 2011-06-22 2016-12-13 Glenmark Pharmaceutical S A composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
CA2841417A1 (en) * 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
WO2013084153A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
US9458173B2 (en) * 2012-06-08 2016-10-04 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
MX363565B (es) 2012-10-01 2019-03-27 Orion Corp Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1.
AP2015008919A0 (en) * 2013-06-20 2015-12-31 Glenmark Pharmaceuticals Sa Nanoparticulate formulation comprising a trpa1 antagonist
JP2016537322A (ja) 2013-10-15 2016-12-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニスト及び鎮痛剤を含む医薬組成物
EP3180337B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2017177200A1 (en) * 2016-04-07 2017-10-12 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
WO2018162607A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
WO2022079092A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Tetrazole derivatives as trpa1 inhibitors
PL4228755T3 (pl) 2020-10-14 2025-04-07 Boehringer Ingelheim International Gmbh Pochodne tetrazolowe jako inhibitory trpa1
JP7565457B2 (ja) 2021-04-14 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＴＲＰＡ１阻害剤としての３Ｈ，４Ｈ－チエノ－［２，３－ｄ］ピリミジン－４－オン誘導体
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DK1107973T3 (da) * 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CA2536313A1 (en) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
JP2007522214A (ja) * 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
EP1847541A4 (en) * 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
AU2006278592A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
JP2009514928A (ja) * 2005-11-08 2009-04-09 ナームローゼ・フエンノートチヤツプ・オルガノン Ｔｒｐｖ１関連障害の治療において有用な２−（ベンゾイミダゾル−１−イル）−ｎ−（４−フェニルチアゾル−２−イル）アセトアミド誘導体
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
CA2634152A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
CN103751194B (zh) * 2007-06-22 2018-01-05 海德拉生物科学公司 用于治疗病症的方法和组合物
CN101711413B (zh) * 2007-06-25 2013-09-04 桑迪士克科技股份有限公司 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
BRPI1013705A2 (pt) 2009-03-23 2016-04-05 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CN102574860A (zh) 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101750125B1 (ko) 2010-01-12 2017-06-22 에이비 사이언스 티아졸 및 옥사졸 키나제 저해제
EA020008B1 (ru) 2010-07-13 2014-07-30 Новартис Аг Производные оксазина и их применение для лечения неврологических нарушений

Also Published As

Publication number Publication date
US20150150876A1 (en) 2015-06-04
IL215175A0 (en) 2011-12-29
US8507503B2 (en) 2013-08-13
ES2424342T3 (es) 2013-10-01
JP2012521406A (ja) 2012-09-13
SI2411396T1 (sl) 2013-07-31
PL2411395T3 (pl) 2013-10-31
CN103755720A (zh) 2014-04-30
CA2756536A1 (en) 2010-09-30
EP2634191A1 (en) 2013-09-04
CN102361874A (zh) 2012-02-22
EP2634191B1 (en) 2014-12-24
SG174404A1 (en) 2011-10-28
BRPI1009381B8 (pt) 2021-05-25
AP2011005889A0 (en) 2011-10-31
BRPI1009381A2 (pt) 2016-06-21
CN102361877B (zh) 2014-05-07
EA201190139A1 (ru) 2012-03-30
EP2411395A1 (en) 2012-02-01
EP2411395B1 (en) 2013-05-29
AU2010227230A2 (en) 2011-10-27
WO2010109334A3 (en) 2010-11-25
SI2634191T1 (sl) 2015-04-30
AU2010227225A1 (en) 2011-09-15
AP2948A (en) 2014-07-31
WO2010109329A1 (en) 2010-09-30
IL215177A (en) 2014-01-30
SI2411395T1 (sl) 2013-07-31
JP5612070B2 (ja) 2014-10-22
ES2424341T3 (es) 2013-10-01
BRPI1013705A2 (pt) 2016-04-05
EP2411396A2 (en) 2012-02-01
AU2010227225A2 (en) 2011-10-06
PE20120775A1 (es) 2012-06-27
DK2411395T3 (da) 2013-08-05
ZA201107649B (en) 2012-07-25
SG184769A1 (en) 2012-10-30
PL2411396T3 (pl) 2013-10-31
SG174398A1 (en) 2011-10-28
JP2012521407A (ja) 2012-09-13
DK2411396T3 (da) 2013-08-05
HUE024538T2 (hu) 2016-01-28
PT2411396E (pt) 2013-06-06
PL2634191T3 (pl) 2015-06-30
KR20110128898A (ko) 2011-11-30
SG184767A1 (en) 2012-10-30
US20130289054A1 (en) 2013-10-31
US9474758B2 (en) 2016-10-25
HK1166074A1 (en) 2012-10-19
IL215175A (en) 2014-01-30
CA2756536C (en) 2015-10-06
BRPI1009381B1 (pt) 2020-04-14
MX2011009822A (es) 2012-01-25
PT2634191E (pt) 2015-03-04
CA2756535A1 (en) 2010-09-30
EA022029B1 (ru) 2015-10-30
PT2411395E (pt) 2013-06-06
CN102361877A (zh) 2012-02-22
KR101524337B1 (ko) 2015-05-29
AU2010227230B2 (en) 2015-11-26
EA201190138A1 (ru) 2013-05-30
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
AU2010227230A1 (en) 2011-09-22
US20120178766A1 (en) 2012-07-12
WO2010109334A2 (en) 2010-09-30
ES2532386T3 (es) 2015-03-26
KR20120004422A (ko) 2012-01-12
US20120295924A1 (en) 2012-11-22
US8987278B2 (en) 2015-03-24
DK2634191T3 (en) 2015-03-23
ZA201107650B (en) 2012-07-25
CN103755720B (zh) 2016-07-06
EP2411396B1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20090641A1 (es) Amidas heterociclicas
PE20100737A1 (es) Nuevos compuestos
AR054799A1 (es) Derivados de oxindol
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20091321A1 (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica
PE20151274A1 (es) Inhibidores de erk y sus usos
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1

Legal Events

Date Code Title Description
FD Application declared void or lapsed